Skip to content

To determine the ocular irritation potential of the test product by direct eye-instillation technique

A Human Ocular Instillation study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/059290
Enrollment
36
Registered
2023-10-30
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Baby Head To Toe Wash: 10 µl of diluted test product to be instilled into conjunctival sac on one eye. Single usage of product. Control Intervention1: Distilled water: 10 µl of control

Sponsors

Uprising Science Pvt. Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy adult non-pregnant/non-lactating females with age 18 to 65 years (both inclusive) at the time of consent. 2. Subjects in general good health as determined by the Investigator on the basis of medical history and with no medical conditions of the eye. 3. Subjects who pass a general eye examination as assessed by Ophthalmologist. 4. Subjects who pass an eye sting evaluation using isotonic saline and an Ophthalmologist Eye evaluation as assessed by Ophthalmologist. 5. Subjects having visual acuity of at least 20/40 (with corrective wear, i.e., glasses but not contact lens).

Exclusion criteria

Exclusion criteria: 1. Subjects wearing any facial and eye makeup including false eye lashes on the day of the study visits. 2. Subjects currently using or have used eye drops (e.g., Visine, Saline Solutions, etc.) within the last 2 weeks. 3. Subjects who ever had any eye conditions such glaucoma, cataracts, exophthalmos (protuberance of eye), etc. 4. Subjects having any eye infections or irritation including blepharitis, general lid inflammation, conjunctivitis, or an eye discharge within 2 weeks of the study. 5. Subjects who had any eye surgery (including Lasik, laser eye surgery). 6. Subjects having any other condition or factor that the Investigator or Ophthalmologist believes may affect the stinging or tearing response or the interpretation of the results.

Design outcomes

Primary

MeasureTime frame
Ophthalmological assessment of Ocular Tolerance of the test product (i.e., degree of inflammation of bulbar and palpebral conjunctiva and lacrimation).Timepoint: Day 01 (30 secs, 3 mins, 5 mins, 10 mins, 15 mins and 60 mins after instillation) Day 02 (24 hrs after instillation)

Secondary

MeasureTime frame
Assessment of self-perceived discomfort using 4-point scale by subjects.Timepoint: Day 01 (30 secs, 15 mins and 60 mins after instillation) Day 02 (24 hrs after instillation)

Countries

India

Contacts

Public ContactDr Simran Sethi

Cliantha Research

pjoshi@cliantha.com8000085049

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026